TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.
TScan Therapeutics has raised $30.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.
TScan Therapeutics's investors include RA Capital Management, BlackRock, Bessemer Venture Partners, Pitango VC, Longwood Fund.
TScan Therapeutics is headquartered in Waltham, United States.
TScan Therapeutics is a biopharmaceutical company focused on the development of immunotherapy treatments for cancer.
TScan Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TScan Therapeutics — Funding & Investors." VCBacked, December 26, 2024, https://www.vcbacked.co/company/tscan-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). TScan Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tscan-therapeutics
{{cite web |title=TScan Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tscan-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated